Drugs / Inclacumab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01815827 | Jun 2013 → Feb 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00760565 | Sep 2008 → Jun 2011 | peripheral arterial disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01327183 | May 2011 → Oct 2012 | myocardial infarction | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT01245634 | Dec 2010 → May 2013 | arterial occlusion | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 33 trials · 2 missed | ||||||
| Phase 3 | NCT05348915 | Mar 2022 → Nov 2025 | sickle cell disease | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04927247 | Dec 2021 → Nov 2023 | sickle cell disease | Pfizer | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT04935879 | Oct 2021 → Jun 2024 | sickle cell disease | Pfizer | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inclacumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04935879 ↗ |
| Known as | LC-1004-002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109488 ↗ |
| Known as | RG1512 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109488 ↗ |
| Known as | RO4905417 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00760565 ↗ |
| Action | Inhibit | “P-Selectin Antagonist Inclacumab” PMID 26796402 ↗ Jan 2016 |
| Modality | Monoclonal antibody | “Recombinant Human Monoclonal Antibody Against P-selectin” NCT01245634 ↗ |
| Route | Intravenous | “Following Intravenous Infusion” NCT00760565 ↗ |
| Target | SELP | “Recombinant Human Monoclonal Antibody Against P-selectin” NCT01245634 ↗ |